Boehringer acquires T3 Pharma
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Search
Agreement-to-acquire-Labor-Dr.-Merk
Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
Are combination therapies the answer to battling KRAS cancers?
Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal
Veganism
Hear an expert’s opinion on the proposed link between a vegan diet and cancer recurrence rates.
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Agreement-to-acquire-NBE-Therapeutics
Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Boehringer Ingelheim advances SIRP immune-oncology program
Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
KISIMA® Cancer Vaccine
KISIMA® Cancer Vaccine
Boehringer Ingelheim - Life Forward
Learn how we change life for the better for people and animals.
Social Support
People living with cancer share their perspectives on the importance of social support.
Physical Wellbeing
Resources and videos related to physical wellbeing whilst living with cancer.
Nutrition
People with cancer discuss the benefits she experienced through making dietary changes whilst undergoing cancer treatment.
Mental Health
Hear the perspectives of people living with cancer on the topic of mental health.
Purpose: Finding the long-missed meaning
Cancer survivor Missy Pappion is happy at Boehringer Ingelheim after climbing the corporate ladder
Collaboration-with-OxfordBioTherapeutics
Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
GioTag Final Data
Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
Advice to Fellow Patients
People living with cancer share their advice for fellow patients, from checking information sources to living in the present moment.
Tips to help you start your patient advocacy journey
Advocating for yourself as a patient can be daunting. Jeff Dunn, President of Union for International Cancer Control (UICC), shares some tips
Partnership canine oncology
The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Dedifferentiated liposarcoma: Life with an ultra rare cancer
For Dan, being diagnosed with dedifferentiated liposarcoma, an ultra rare sarcoma, was life changing, and means he now makes the most of every day.
Our goal of transforming the treatment of neuroendocrine carcinomas
Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).
Sarcoma
Hear from Gary Schwartz, MD, Director of the Case Comprehensive Cancer Center, Cleveland, Ohio, talk about his expert perspectives on sarcoma.
Combination Therapy
It’s the smart combination of our cancer cell-directed and immuno-oncology approaches that may offer the greatest benefit for people living with cancer.
TCO patient podcasts
From clinical trials to living with cancer, hear patient perspectives on different cancer topics in this podcast series.